Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 2/20 | 0.41 |
| ▸ | NMT1 | P30419 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | ALB | P02768 | 3/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19062765 | 0.92 | NMT1 (0.49) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL23626256 | 0.90 | NMT2 (0.42) | NMT2NMT1NAMPTGLP1RALB | |
| SCHEMBL18513361 | 0.88 | NMT2 (0.40) | NMT2NMT1NAMPTGLP1RALB | |
| SCHEMBL22692615 | 0.87 | NMT2 (0.47) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL16248536 | 0.87 | NAMPT (0.40) | NMT2NMT1NAMPTALBNOD1 | |
| SCHEMBL24239548 | 0.87 | OPRK1 (0.33) | NMT2NMT1 | |
| SCHEMBL19062769 | 0.87 | OPRK1 (0.33) | NMT2NMT1 | |
| SCHEMBL18513227 | 0.86 | NMT1 (0.54) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL17589403 | 0.84 | LMNA (0.39) | NMT2NMT1NAMPTALBNOD1 | |
| SCHEMBL22692674 | 0.83 | NMT1 (0.52) | NMT2NMT1GLP1RNOD1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-9943604-B2 | Targeted therapeutic nucleosides and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | NMT2 36/4885NMT1 20/4885NAMPT 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.